Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4721644 | 0.92 | GPR119 (0.46) | GPR119CYP3A4CYP2C9CCNA2CDK2 | |
| SCHEMBL4724409 | 0.91 | GPR119 (0.48) | GPR119CYP3A4CYP2C9CCNA2CDK2 | |
| SCHEMBL4722991 | 0.90 | GPR119 (0.54) | GPR119CYP2C9CCNA2CDK2CDK5 | |
| SCHEMBL390975 | 0.90 | CYP3A4 (0.57) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL4723222 | 0.90 | GPR119 (0.38) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL4720553 | 0.88 | S1PR1 (0.37) | GPR119 | |
| SCHEMBL4722413 | 0.86 | GPR119 (0.50) | GPR119CYP3A4CYP2C9CCNA2CDK2 | |
| SCHEMBL4721977 | 0.86 | GPR119 (0.43) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL4719712 | 0.86 | S1PR1 (0.36) | GPR119 | |
| SCHEMBL4719082 | 0.86 | GPR119 (0.52) | GPR119CYP3A4CYP2C9CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756084-B1 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2008-11-26 | — | — | EP | claimed |